Home  /  Resource Library  /  Economic Burden of Neurologic Toxicities Associated with Treating Relapsed Refractory Diffuse Large B-Cell Lymphoma in the United States

Economic Burden of Neurologic Toxicities Associated with Treating Relapsed Refractory Diffuse Large B-Cell Lymphoma in the United States

ASH 2019: Study examined the financial burden of patients with relapsed DLBCL being treated for neurological side effects.